Abcl stock forecast.

ABCL Stock Performance on October 13, 2023: Overview, Analysis, and Projections. ABCL Stock Performance on October 13, 2023: – Previous close on October 12, 2023: $4.39 – Opening price on October 13, 2023: $4.41 – Range of fluctuation: $3.92 to $4.41 – Trading volume on October 13, 2023: 4,206,194 shares

Abcl stock forecast. Things To Know About Abcl stock forecast.

Per our algorithmic AbCellera Biologics stock forecast, ABCL’s price could see a decrease of -13.49% over the next five days and reach $ 4.14 on Dec 05, 2023. In the next month, AbCellera Biologics stock is forecasted to lose -1.11% and hit $ …Abcam plc () Stock Market info Recommendations: Buy or sell Abcam stock? London Stock Market & Finance report, prediction for the future: You'll find the Abcam share forecasts, stock quote and buy / sell signals below.According to present data Abcam's ABC shares and potentially its market environment have been in bearish cycle last 12 months …2 days ago · Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $23.29, which predicts an increase of 436.64%. The lowest target is $12 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy. Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Dec 31, 2020 · ABCL's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks). ABCL Stock Summary. The price/operating cash flow metric for ABCELLERA BIOLOGICS INC is higher than 98.57% of stocks in our set with a positive cash flow. ABCL's price/sales ratio is 23.26; that's higher than the P/S ratio of 95.29% of US stocks.

AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).AbCellera Biologics Stock Chart and Share Price Forecast, Short-Term "ABCL" Stock Prediction for Next Days and Weeks Walletinvestor.com AbCellera Biologics Inc (ABCL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024

Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast."ABCL" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "ABCL" projections. At Walletinvestor.com we …

AB Capital Share Price: Find the latest news on AB Capital Stock Price. Get all the information on AB Capital with historic price charts for NSE / BSE. Experts & Broker view also get the AB ...AmerisourceBergen stock forecast report. View ABC price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.As a result, it might be a surprise to see that the analysts have cut their price target 10% to US$30.00, which could suggest the forecast improvement in performance is not expected to last.Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.

Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 20.50, with a high estimate of 34.00 and a low estimate of 10.00. The median estimate represents a +323.99% increase from the last price of 4.84.

Real time AbCellera Biologics (ABCL) stock price quote, stock graph, news & analysis.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices. Compare ABCL With Other Stocks. AbCellera Biologics PE Ratio ...Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 24.35 USD with a low forecast of 12.12 USD and a high forecast of 35.7 USD. ABCL Lowest Forecast Wall Street Target. 12.12 ...Jul 19, 2023 · Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts ABCL's market cap stands at $2.07B, with total debt ... The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors? Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.48) to ($0.60) per share. AbCellera Biologics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off prior year's report dates. Read More.More than 80 oyster farms on the NSW South Coast remain closed after severe storms and flooding hit this week. It's a flip of the coin as to whether they'll be open in …Nov 21, 2023 · Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years.

For Abcam plc stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Abcam plc stock forecast of 1878.0, a high forecast of 2240.87, and a low forecast of 1688.28. The average Abcam plc stock forecast 2026 represents a 53.18% increase from the last price of 1226.0.Find the latest AbCellera (NASDAQ: ABCL) stock information.16:00 EST ABCL Stock Quote Delayed 30 Minutes ... ABCL Stock Predictions, Articles, and Abcellera Biologics Inc News From InvestorPlace From the Web 7 Best Stocks Under $10 to Buy in April ...AbCellera Biologics (ABCL) Stock Forecast & Price Target $4.43 0.00 (0.00%) (As of 11/24/2023 ET) Compare Today's Range $4.40 $4.49 50-Day Range $3.91 $5.13 52 …Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 20.50, with a high estimate of 34.00 and a low estimate of 10.00. The median estimate represents a +323.99% increase from the last price of 4.84.

So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -256.27% -223.52%See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.hace 4 días ... AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value on Thursday, November 30, with the stock price down by -0.31% to the previous ...According to our current ABCL stock forecast, the value of AbCellera Biologics shares will drop by -6.13% and reach $ 4.40 per share by December 6, 2023. …Now, shares are making a pullback to their 21-day line, creating a high handle for that cup base, and could offer investors a new entry. ABCL stock slipped 1.5% to close at 13.36 on the stock ...Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

hace 4 días ... AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value on Thursday, November 30, with the stock price down by -0.31% to the previous ...

ABCL's price/sales ratio is 23.26; that's higher than the P/S ratio of 95.29% of US stocks. Revenue growth over the past 12 months for ABCELLERA BIOLOGICS INC comes in at -91.65%, a number that bests just 1.31% of the US stocks we're tracking. Stocks that are quantitatively similar to ABCL, based on their financial statements, market ...

Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8. Dec 1, 2023 · ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million. Aditya Birla Cap. share price was Rs 169.90 as on 01 Dec, 2023, 03:59 PM IST. Aditya Birla Cap. share price was up by 1.13% based on previous share price of Rs. 169.15. In last 1 Month, Aditya Birla Cap. share price moved down by 0.12%. 2.JYNT. The Joint Corp. 9.24. -0.01. -0.11%. In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap ...Oct 13, 2023 · According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97. View the ABCL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abcellera Biologics Inc real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view …Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.Aditya Birla Cap. share price was Rs 169.90 as on 01 Dec, 2023, 03:59 PM IST. Aditya Birla Cap. share price was up by 1.13% based on previous share price of Rs. 169.15. In last 1 Month, Aditya Birla Cap. share price moved down by 0.12%. 2.Jazz actually didn't own Epidiolex at that time. It acquired GW Pharmaceuticals, which developed the CBD drug to treat epileptic seizures, for $6.7 billion in 2021 . Epidiolex is still a long way ...Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The …According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecasts

52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.Business Finance Consider company ABC. Today it is 1st of January 2023 and ABC has just paid a dividend of £3 million. The expected earnings of ABC for the next 30 years are forecast to grow at a rate of 15% per annum. From 1st of January 2053 and onwards the earnings of ABC are expected to grow at a rate of 5%.ABCL Stock Analysis: Impressive Performance and Optimistic Analyst Forecasts ABCL stock had an impressive performance on September 20, 2023, based on the information provided. The 7 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00.Instagram:https://instagram. hvac stocksspy dividend calculatornasdaq graph historyacvf Nov 29, 2023 · Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low. According to the issued ratings of 4 analysts in the last year, the consensus rating for Coupang stock is Moderate Buy based on the current 2 hold ratings and 2 buy ratings for CPNG. The average twelve-month price prediction for Coupang is $22.50 with a high price target of $25.00 and a low price target of $20.00. buying a nftdoes liberty mutual offer pet insurance AbCellera Biologics Stock Forecast. Is AbCellera Biologics Stock Undervalued? The current AbCellera Biologics [ ABCL] share price is $4.47. The Score for ABCL is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. ABCL is currently trading in the 40-50% percentile range relative to its historical Stock ... stock upgrade downgrade AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8.